Related Experiment Video
Updated: Jun 27, 2026

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
Published on: May 29, 2020
Fulminant hepatitis induced by lamotrigine.
Georges Ouellet1, Lydjie Tremblay, Denis Marleau
1Department of Medicine, Centre Hospitalier de l'Université de Montréal, Montréal, Québec, Canada.
Anticonvulsant hypersensitivity syndrome (AHS) can cause severe reactions like hepatitis. This case highlights that AHS with fulminant hepatitis from lamotrigine can occur unpredictably, regardless of drug dosage or other medications.
Area of Science:
- Pharmacology
- Hepatology
- Clinical Toxicology
Background:
- Anticonvulsant hypersensitivity syndrome (AHS) is a severe, idiosyncratic drug reaction.
- It typically presents with fever, rash, and systemic organ involvement.
- Hepatitis is a rare but serious manifestation of AHS.
Observation:
- A 40-year-old female with bipolar disorder developed AHS with fulminant hepatitis.
- The reaction occurred two weeks after initiating lamotrigine (25 mg, titrated to 50 mg).
- The patient had no prior organ issues or concurrent medications.
Findings:
- Lamotrigine hypersensitivity can manifest as severe, acute hepatitis.
- The idiosyncratic reaction occurred despite low dosage and slow titration.
- Cessation of lamotrigine led to favorable patient recovery.
Implications:
- AHS with hepatitis may be idiosyncratic and not solely dose-dependent.
- Clinicians should consider AHS in patients with unexplained hepatitis after starting anticonvulsants.
- Early recognition and drug withdrawal are crucial for managing severe AHS cases.
Related Concept Videos
Antiepileptic Drugs: Glutamate Antagonists
Mania and Antimanic Drugs: Overview
Hepatic Encephalopathy
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...